List of Excipients in Branded Drug VIMOVO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	VIMOVO	naproxen and esomeprazole magnesium	16590-957	CARNAUBA WAX
STAT RX USA LLC	VIMOVO	naproxen and esomeprazole magnesium	16590-957	CROSCARMELLOSE SODIUM
STAT RX USA LLC	VIMOVO	naproxen and esomeprazole magnesium	16590-957	FERRIC OXIDE YELLOW

VIMOVO Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 26, 2026

VIMOVO is a fixed-dose delayed-release tablet combining naproxen 500 mg with esomeprazole magnesium 20 mg. Its commercial value comes from coordinated release: esomeprazole is released first to reduce naproxen-associated upper-gastrointestinal risk, while naproxen is protected from gastric release through enteric coating. The formulation creates opportunities for specialty generics, alternate-strength products, co-packaged therapies, excipient suppliers, and differentiated 505(b)(2) products. It also creates meaningful technical barriers because the two active ingredients require different dissolution environments and stability controls.

What is VIMOVO and how does its formulation work?

VIMOVO is approved for adults who require naproxen treatment and need a reduced risk of developing gastric ulcers associated with naproxen use. It is not intended to eliminate all gastrointestinal risk from naproxen and is not interchangeable with separate over-the-counter naproxen and proton-pump inhibitor products without considering dose, timing, and release characteristics (AstraZeneca, 2022).

Attribute	VIMOVO specification
Active ingredients	Naproxen and esomeprazole magnesium
Strength	Naproxen 500 mg/esomeprazole 20 mg
Dosage form	Delayed-release tablet
Route	Oral
Naproxen dose	500 mg
Esomeprazole dose	20 mg
FDA application	NDA 022560
Original approval	April 2010
Primary therapeutic use	NSAID therapy with reduced risk of naproxen-associated gastric ulcers
Product architecture	Immediate-release esomeprazole component plus delayed-release naproxen component

The formulation uses a multilayer approach. Esomeprazole is released rapidly after ingestion. Naproxen remains protected until the tablet reaches the higher-pH environment of the small intestine. This architecture avoids simultaneous gastric exposure to naproxen and provides a practical alternative to administering a separate NSAID and proton-pump inhibitor.

What release sequence does VIMOVO require?

The target release sequence is:

1. Rapid esomeprazole release in the stomach.
2. Protection of naproxen from acidic gastric conditions.
3. Naproxen release after exposure to intestinal pH.
4. Reproducible dissolution across fed and fasted conditions.

This sequence creates a more demanding development problem than a conventional immediate-release combination tablet. The developer must control the location and timing of each active ingredient, not merely the total dose.

What excipients are used in VIMOVO?

The FDA prescribing information identifies excipients associated with tablet processing, compression, coating, stability, and appearance. Public labeling identifies materials including croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, titanium dioxide, triethyl citrate, and iron oxide-based colorants, although the precise role and quantity of each excipient are controlled by the manufacturing process and master batch record (AstraZeneca, 2022).

Excipient class	Likely formulation role	Commercial significance
Croscarmellose sodium	Disintegrant for rapid release	Supports prompt esomeprazole release
Povidone	Binder and granulation aid	Supports mechanical strength and content uniformity
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and may reduce processing variability
Magnesium stearate	Lubricant	Controls ejection force but can slow wetting if overused
Hypromellose	Film-forming and coating polymer	Supports protective and enteric coating systems
Talc	Anti-tacking and coating aid	Improves coating performance
Triethyl citrate	Plasticizer	Reduces brittleness in polymeric coatings
Titanium dioxide	Opacifier and pigment	Improves appearance and light protection
Iron oxide colorants	Tablet identification	Supports product differentiation and dose recognition

Exact quantitative composition should not be inferred from the ingredient list. A generic manufacturer can use different excipients if the product meets pharmaceutical equivalence, bioequivalence, dissolution, stability, and quality requirements.

How should an excipient strategy be designed for VIMOVO?

The central excipient strategy is to preserve functional separation between esomeprazole and naproxen. Esomeprazole is acid-labile, while naproxen requires delayed intestinal release. The excipient system therefore has to address chemical stability, release timing, coating integrity, compression, and scale-up.

How can excipients stabilize esomeprazole?

Esomeprazole is vulnerable to acid degradation and can be sensitive to moisture and microenvironmental pH. A generic or reformulated product may need:

• An alkaline stabilizing environment.
• Low-moisture excipients.
• Rapid disintegration for the esomeprazole fraction.
• Protection from acidic processing conditions.
• Controlled exposure to water during granulation and coating.
• Packaging with strong moisture-barrier properties.

The choice between aqueous and nonaqueous processing is commercially important. Aqueous processing can reduce solvent-related manufacturing burdens, but it may increase exposure to moisture and affect esomeprazole stability. Organic or low-water processing can improve stability but raises solvent-handling, residual-solvent, environmental, and scale-up costs.

Which excipients support delayed naproxen release?

The naproxen fraction generally requires an enteric barrier. Polymer selection can include hypromellose phthalate, hypromellose acetate succinate, methacrylic acid copolymers, or other pharmaceutically accepted enteric systems. The commercial choice depends on:

• Dissolution threshold and onset.
• Coating weight gain.
• Film flexibility.
• Resistance to gastric fluid.
• Release in intestinal buffer.
• Compatibility with plasticizers and pigments.
• Availability from qualified suppliers.
• Regulatory precedent.

A lower coating weight can improve manufacturing economics but may increase risk of premature release, pinholes, or variability. A heavier coating improves protection but increases tablet size, process time, and cost.

What are the key excipient compatibility risks?

The primary risks include:

• Esomeprazole degradation caused by acidic excipients.
• Moisture migration between layers.
• Interaction between alkaline stabilizers and coating polymers.
• Over-lubrication that slows disintegration.
• Coating defects caused by tablet surface roughness.
• Mechanical damage during packaging and transportation.
• Inconsistent dissolution after long-term storage.
• Colorant or titanium dioxide changes under evolving regulatory requirements.

A robust development program should assess active-excipient compatibility under heat, humidity, light, and mechanical stress. It should also evaluate dissolution after accelerated and long-term storage rather than relying only on initial release testing.

What formulation patents protect VIMOVO?

VIMOVO-related patent protection has focused on combination products containing a proton-pump inhibitor and an NSAID, release sequencing, dosage forms, and methods of reducing NSAID-associated gastrointestinal injury. Publicly reported U.S. litigation identified patents including U.S. Patent Nos. 6,926,907 and 8,496,965 in disputes involving generic versions of VIMOVO (U.S. District Court records; USPTO, n.d.).

Patent	General subject matter	Strategic relevance
U.S. 6,926,907	Combination pharmaceutical composition involving an NSAID and proton-pump inhibitor	Core combination and formulation protection
U.S. 8,496,965	Later-generation formulation protection associated with the VIMOVO product	Potential barrier to generic approval or launch
Orange Book-listed patents	Product and method-of-use claims submitted by the NDA holder	Determines certification and litigation exposure

Patent scope depends on the asserted claims, prosecution history, terminal disclaimers, patent-term adjustment, and Orange Book listing status. Patent expiration should be confirmed against the current FDA Orange Book and USPTO records rather than inferred from the grant date. Regulatory exclusivity and patent term are separate rights.

When did VIMOVO lose exclusivity?

VIMOVO’s five-year new chemical entity exclusivity period expired in 2015, although that period did not necessarily determine the date of generic market entry. Patent disputes, Paragraph IV certifications, settlements, regulatory review, manufacturing readiness, and court orders can delay or permit launch.

The principal commercial question is not whether FDA exclusivity expired. It is whether a generic applicant can obtain approval without infringing enforceable claims or whether the applicant has reached a settlement allowing entry on a specified date.

What is the Orange Book status of VIMOVO?

The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity associated with approved products. VIMOVO is a small-molecule NDA product, not a biologic licensed under the Public Health Service Act. Its generic pathway is therefore an ANDA pathway, not a biosimilar pathway.

Applicants may submit:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if the patent has expired.
• Paragraph III certification accepting delayed approval until patent expiration.
• Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV notice can trigger a 45-day period for the NDA holder or patent owner to file infringement litigation. A timely suit generally can impose a 30-month stay on ANDA approval, subject to statutory exceptions and court developments (FDA, 2024a).

Which companies have challenged VIMOVO patents?

Public litigation records have identified generic-drug challenges involving companies seeking approval for naproxen and esomeprazole magnesium delayed-release products. Dr. Reddy’s Laboratories has been involved in publicly reported VIMOVO-related patent litigation. The relevant competitive set can change as ANDAs are withdrawn, settled, approved, or transferred.

The practical market-screening task is to distinguish among:

1. Filed ANDAs.
2. Paragraph IV notices.
3. Active district-court litigation.
4. Tentative approvals.
5. Final approvals.
6. Authorized generic arrangements.
7. Settlements with permitted launch dates.

A litigation filing does not establish that a generic will launch. Conversely, a settlement can create a commercial entry date before the last asserted patent expires.

What patent litigation and settlements affect VIMOVO generic entry?

VIMOVO litigation risk concentrates in four areas:

• Whether the generic reproduces the claimed release architecture.
• Whether the proposed formulation infringes composition or manufacturing claims.
• Whether method-of-use claims remain relevant to the ANDA label.
• Whether the patent owner can enforce claims after narrowing amendments or prosecution-history estoppel.

Potential settlement structures include an agreed launch date, a license for limited strengths, an authorized generic arrangement, or restrictions tied to patent validity. Settlement terms may be confidential, and publicly available court orders may disclose only portions of the commercial arrangement.

For a generic developer, a non-infringing design can be more valuable than a direct formulation copy. Changing the coating polymer, layer arrangement, excipient system, or manufacturing sequence may reduce infringement exposure, but it can create new bioequivalence and regulatory burdens.

What commercial opportunities exist in VIMOVO excipients and formulation development?

Which excipient suppliers could benefit?

The most relevant supplier opportunities involve:

• Enteric polymers.
• Plasticizers such as triethyl citrate.
• Low-moisture diluents and binders.
• Superdisintegrants.
• Film-coating systems.
• Moisture-barrier packaging.
• Colorants and opacifiers.
• Functional excipient premixes.

Suppliers can create value by offering validated grade consistency, low elemental impurities, low bioburden, reliable global supply, and technical support for coating and scale-up. A supplier with a regulatory dossier and established pharmaceutical customers may have an advantage over a lower-cost commodity source.

Can a 505(b)(2) product compete with VIMOVO?

A 505(b)(2) strategy could target a differentiated combination or delivery profile rather than an exact ANDA copy. Potential concepts include:

• Alternative naproxen/esomeprazole strengths.
• Modified tablet size for swallowing difficulty.
• A capsule or multiparticulate presentation.
• A product optimized for lower pill burden.
• A co-packaged or synchronized dosing system.
• A formulation designed for a specific patient population.
• An alternate proton-pump inhibitor combined with naproxen.

A 505(b)(2) application must address the extent to which it relies on FDA’s prior findings for VIMOVO or other reference products. Clinical bridging, comparative pharmacokinetics, dissolution, and new patent claims may be required.

How does VIMOVO compare with separate naproxen and proton-pump inhibitor therapy?

Factor	VIMOVO	Separate naproxen plus PPI
Pill burden	One tablet	Usually two products
Dose coordination	Fixed	Adjustable
Release sequence	Engineered into one product	Depends on administration timing
Dose flexibility	Limited	Higher
Formulation complexity	High	Lower at the individual-product level
Generic substitution	Requires matching combination product	Multiple substitution options
Commercial differentiation	Combination convenience and coordinated release	Price and prescribing flexibility

VIMOVO’s commercial advantage is convenience and integrated release. Its disadvantage is fixed dosing. Patients needing lower naproxen exposure or a different PPI dose may prefer separate products.

What generic launch scenarios exist for VIMOVO?

Scenario	Market effect
No approved generic	Branded product retains substantial price control
Single generic launch	Price erosion may be moderate initially
Several ANDA approvals	Rapid discounting and channel competition
Authorized generic	Earlier or controlled erosion through the brand owner
Non-infringing 505(b)(2) product	Differentiated competition without exact ANDA substitution
Generic shortage or manufacturing failure	Temporary price and supply volatility
Settlement-based entry	Predictable but potentially delayed competition

Revenue exposure depends on the number of approved competitors, payer substitution rules, launch timing, wholesale acquisition price, and the share of prescriptions that require the fixed-dose combination. Products with limited generic competition can retain meaningful revenue even after core patent expiry, but price pressure usually increases once multiple therapeutically equivalent products enter the market.

How strong is the VIMOVO patent estate?

The estate has historically had meaningful value because it combines formulation, release, and method-of-use concepts. Its strength is reduced when:

• Claims require narrow structural features that can be designed around.
• Prior art discloses NSAID/PPI combinations.
• The generic uses a different coating polymer or layer configuration.
• Method-of-use claims are difficult to enforce against an ANDA label.
• Patent terms approach expiration.
• The product can be replicated through standard enteric-coating technology.

The strongest commercial protection generally comes from claims that connect the specific release sequence to measurable dissolution or pharmacokinetic performance. Broad claims to the concept of combining naproxen with a proton-pump inhibitor face greater validity and design-around pressure.

What manufacturing and geographic barriers affect VIMOVO competition?

Manufacturing barriers include multilayer compression or layered granulation, precise coating control, low-moisture processing, and dissolution testing across multiple stages. A manufacturer must also qualify suppliers for enteric polymers, plasticizers, lubricants, and packaging materials.

Geographic considerations include:

• U.S. Orange Book listings and ANDA litigation.
• European national and centralized regulatory requirements.
• Local patent-term differences.
• Excipient and coating-material registration requirements.
• Import controls and supply-chain qualification.
• Regional substitution rules.
• Country-specific labeling and reimbursement.

A formulation approved in the United States may require additional work in Europe or other markets because reference-product, bioequivalence, labeling, and patent rules differ.

What are the key commercial opportunities?

The highest-value opportunities are:

1. Generic VIMOVO products using a reliable, non-infringing delayed-release design.
2. Excipient platforms that stabilize acid-labile proton-pump inhibitors.
3. Lower-cost enteric-coating systems with equivalent dissolution performance.
4. 505(b)(2) products with flexible dosing or alternate dosage forms.
5. Contract development and manufacturing services for multilayer tablets.
6. Packaging systems that improve moisture protection without increasing cost.
7. Regional licensing of generic or reformulated products.
8. Authorized-generic or supply agreements linked to patent settlements.

Key Takeaways

• VIMOVO combines naproxen 500 mg and esomeprazole magnesium 20 mg in a delayed-release tablet.
• Its core technical challenge is coordinating immediate esomeprazole release with delayed naproxen release.
• Croscarmellose sodium, povidone, hypromellose, talc, triethyl citrate, magnesium stearate, and colloidal silicon dioxide support different functional requirements.
• Esomeprazole stability, moisture control, enteric coating integrity, and dissolution are the main development risks.
• VIMOVO is a small-molecule product subject to ANDA competition, not biosimilar competition.
• Publicly reported patent litigation has involved U.S. Patent Nos. 6,926,907 and 8,496,965.
• Generic launch timing depends on current Orange Book listings, Paragraph IV activity, litigation, settlements, and regulatory approvals.
• The strongest commercial opportunities are in non-infringing generics, excipient platforms, 505(b)(2) products, coating technologies, and specialized manufacturing.

FAQs

Is VIMOVO a biologic subject to biosimilar competition?

No. VIMOVO is a small-molecule combination product. Competition generally proceeds through ANDAs or, for differentiated products, 505(b)(2) applications.

Can a generic VIMOVO use different excipients?

Yes. A generic may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, dissolution, and safety.

What is the main formulation barrier for generic VIMOVO?

The main barrier is reproducing the required release sequence while maintaining esomeprazole stability and protecting naproxen from gastric release.

Does VIMOVO’s fixed dose limit commercial growth?

Yes. The 500 mg naproxen/20 mg esomeprazole ratio limits dose flexibility compared with prescribing the two active ingredients separately.

Are enteric polymers the most important excipient opportunity?

They are among the most important. Enteric polymers directly affect gastric resistance, intestinal release, coating weight, manufacturing time, and generic bioequivalence risk.

References

AstraZeneca. (2022). VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets: Prescribing information. U.S. Food and Drug Administration.

Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024b). Abbreviated new drug application submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.

U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment Search. U.S. Department of Commerce.

U.S. District Court. (n.d.). VIMOVO-related patent litigation records involving generic applicants. PACER federal court records.